Program
anvatabart opadotin
Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung, led by 2 companies.
Furthest: phase 2, since Mar 18, 20214 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 31 open or running | phase 2since Mar 18, 2021 | Aug 14, 2017 | Dec 2026phase 2 · NCT04829604 |
| Zhejiang Medicine | 10 open or running | phase 1since Jun 22, 2015 | Jun 22, 2015 | none ahead |
- Named in Johnson & Johnson’s own pipeline as
JNJ-0683 (ARX788)
, phase 2, as of Oct 13, 2026 (source).
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 22, 2015First study: phase 1 study in Breast NeoplasmsNew to Zhejiang MedicineZhejiang Medicine · NCT02512237 · 9 enrolled · Australia, New Zealand
- Aug 14, 2017Johnson & Johnson’s first study: phase 1 study in Breast NeoplasmsNew to Johnson & JohnsonJohnson & Johnson · NCT03255070 · 106 enrolled · United States, Australia
- Mar 18, 2021Phase 2 study in Breast NeoplasmsJohnson & Johnson · NCT04829604 · 72 enrolled · United States, Australia, South Korea
- Sep 3, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungJohnson & Johnson · NCT05041972 · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Breast NeoplasmsJohnson & Johnson · NCT04829604
TargetBeta
“An antibody-drug conjugate (ADC) composed of anvatabart, a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2) site-specifically conjugated at two engineered residues of para-acetyl-phenylalanine (pAcF) via a stable oxime linker to the monomethyl auristatin F (MMA…”NCIt, read by Claude
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05041972Carcinoma, Non-Small-Cell Lung · United States | 2 | Withdrawn | Johnson & Johnson | Apr 20, 2022 | 0 |
| NCT04829604Breast Neoplasms · United States, Australia, South Korea | 2 | Active, not recruiting | Johnson & Johnson | Dec 2026 | 72 |
| NCT03255070Breast Neoplasms · United States, Australia | 1 | Completed | Johnson & Johnson | Sep 13, 2023 | 106 |
| NCT02512237Breast Neoplasms · Australia, New Zealand | 1 | Terminated | Zhejiang Medicine | Jan 2017 | 9 |
How it is read
Names in the registry
- “ARX788”, 4 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.